82 related articles for article (PubMed ID: 18642214)
1. Highly iodinated intravenous contrast material for PET/CT - a feasibility study.
Heusner TA; Kuehl H; Veit-Haibach P; Hahn S; Boy C; Forsting M; Bockisch A; Antoch G
Rofo; 2008 Aug; 180(8):740-5. PubMed ID: 18642214
[TBL] [Abstract][Full Text] [Related]
2. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error?
Yau YY; Chan WS; Tam YM; Vernon P; Wong S; Coel M; Chu SK
J Nucl Med; 2005 Feb; 46(2):283-91. PubMed ID: 15695788
[TBL] [Abstract][Full Text] [Related]
3. Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging.
Brechtel K; Klein M; Vogel M; Mueller M; Aschoff P; Beyer T; Eschmann SM; Bares R; Claussen CD; Pfannenberg AC
J Nucl Med; 2006 Mar; 47(3):470-6. PubMed ID: 16513616
[TBL] [Abstract][Full Text] [Related]
4. Integrated whole-body PET/MR hybrid imaging: clinical experience.
Quick HH; von Gall C; Zeilinger M; Wiesmüller M; Braun H; Ziegler S; Kuwert T; Uder M; Dörfler A; Kalender WA; Lell M
Invest Radiol; 2013 May; 48(5):280-9. PubMed ID: 23442775
[TBL] [Abstract][Full Text] [Related]
5. Nonionic intravenous contrast agent does not cause clinically significant artifacts to 18F-FDG PET/CT in patients with lung cancer.
An YS; Sheen SS; Oh YJ; Hwang SC; Yoon JK
Ann Nucl Med; 2007 Dec; 21(10):585-92. PubMed ID: 18092135
[TBL] [Abstract][Full Text] [Related]
6. Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT.
Beyer T; Antoch G; Bockisch A; Stattaus J
J Nucl Med; 2005 Mar; 46(3):429-35. PubMed ID: 15750155
[TBL] [Abstract][Full Text] [Related]
7. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data.
Martinez-Möller A; Souvatzoglou M; Delso G; Bundschuh RA; Chefd'hotel C; Ziegler SI; Navab N; Schwaiger M; Nekolla SG
J Nucl Med; 2009 Apr; 50(4):520-6. PubMed ID: 19289430
[TBL] [Abstract][Full Text] [Related]
8. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
[TBL] [Abstract][Full Text] [Related]
9. Whole-body 18F-FDG PET/CT in the presence of truncation artifacts.
Beyer T; Bockisch A; Kühl H; Martinez MJ
J Nucl Med; 2006 Jan; 47(1):91-9. PubMed ID: 16391192
[TBL] [Abstract][Full Text] [Related]
10. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
11. Impact of time-of-flight PET on quantification errors in MR imaging-based attenuation correction.
Mehranian A; Zaidi H
J Nucl Med; 2015 Apr; 56(4):635-41. PubMed ID: 25745090
[TBL] [Abstract][Full Text] [Related]
12. 18F-fluoride PET/CT for bone scanning. Role of attenuation correction.
Nagarajah J; Dannat T; Hartung V; Bockisch A; Rosenbaum-Krumme S
Nuklearmedizin; 2012; 51(3):84-7. PubMed ID: 22366817
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of low-density neutral oral contrast material in PET/CT for tumor imaging: results of a randomized clinical trial.
Otero HJ; Yap JT; Patak MA; Erturk SM; Israel DA; Johnston CJ; Sakellis C; Rybicki FJ; Van den Abbeele AD; Ros PR
AJR Am J Roentgenol; 2009 Aug; 193(2):326-32. PubMed ID: 19620427
[TBL] [Abstract][Full Text] [Related]
14. Body surface area adapted iopromide 300 mg/ml versus 370 mg/ml contrast medium injection protocol: influence on quantitative and clinical assessment in combined PET/CT.
Verburg FA; Apitzsch J; Lensing C; Kuhl CK; Pietsch H; Mottaghy FM; Behrendt FF
Eur J Radiol; 2013 Dec; 82(12):2348-52. PubMed ID: 24113432
[TBL] [Abstract][Full Text] [Related]
15. Respiratory-gated ¹⁸F-FDG PET/CT for the diagnosis of liver metastasis.
Suenaga Y; Kitajima K; Aoki H; Okunaga T; Kono A; Matsumoto I; Fukumoto T; Tanaka K; Sugimura K
Eur J Radiol; 2013 Oct; 82(10):1696-701. PubMed ID: 23768610
[TBL] [Abstract][Full Text] [Related]
16. Adequate evaluation of image registration in hybrid PET/CT.
Vogel WV; van Dalen JA; Oyen WJ
J Nucl Med; 2006 Sep; 47(9):1556; author reply 1557-8. PubMed ID: 16954568
[No Abstract] [Full Text] [Related]
17. Evaluation of scatter limitation correction: a new method of correcting photopenic artifacts caused by patient motion during whole-body PET/CT imaging.
Miwa K; Umeda T; Murata T; Wagatsuma K; Miyaji N; Terauchi T; Koizumi M; Sasaki M
Nucl Med Commun; 2016 Feb; 37(2):147-54. PubMed ID: 26440565
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous reconstruction of activity and attenuation for PET/MR.
Salomon A; Goedicke A; Schweizer B; Aach T; Schulz V
IEEE Trans Med Imaging; 2011 Mar; 30(3):804-13. PubMed ID: 21118768
[TBL] [Abstract][Full Text] [Related]
19. Correction for oral contrast artifacts in CT attenuation-corrected PET images obtained by combined PET/CT.
Nehmeh SA; Erdi YE; Kalaigian H; Kolbert KS; Pan T; Yeung H; Squire O; Sinha A; Larson SM; Humm JL
J Nucl Med; 2003 Dec; 44(12):1940-4. PubMed ID: 14660720
[TBL] [Abstract][Full Text] [Related]
20. Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging.
Pfannenberg AC; Aschoff P; Brechtel K; Müller M; Klein M; Bares R; Claussen CD; Eschmann SM
Br J Radiol; 2007 Jun; 80(954):437-45. PubMed ID: 17329683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
